1. Acetylshikonin Inhibits Human Pancreatic PANC-1 Cancer Cell Proliferation by Suppressing the NF-κB Activity
- Author
-
Seok-Cheol Cho and Bu Young Choi
- Subjects
medicine.medical_treatment ,Acetylshikonin ,medicine.disease_cause ,Biochemistry ,NF-κB ,chemistry.chemical_compound ,Drug Discovery ,Tumor necrosis-α ,medicine ,Pharmacology ,business.industry ,Cancer ,Pancreatic cancer ,NFKB1 ,medicine.disease ,Matrix metalloproteinase ,Cytokine ,chemistry ,Cancer cell ,Immunology ,Phorbol ,Cancer research ,Molecular Medicine ,Phorbol 12-myristate 13-acetate ,Tumor necrosis factor alpha ,Original Article ,Carcinogenesis ,business - Abstract
Acetylshikonin, a natural naphthoquinone derivative compound, has been used for treatment of inflammation and cancer. In the present study, we have investigated whether acetylshikonin could regulate the NF-κB signaling pathway, thereby leading to suppression of tumorigenesis. We observed that acetylshikonin significantly reduced proliferation of several cancer cell lines, including human pancreatic PANC-1 cancer cells. In addition, acetylshikonin inhibited phorbol 12-myristate 13-acetate (PMA) or tumor necrosis-α (TNF-α)-induced NF-κB reporter activity. Proteome cytokine array and real-time RT-PCR results illustrated that acetylshikonin inhibition of PMA-induced production of cytokines was mediated at the transcriptional level and it was associated with suppression of NF-κB activity and matrix metalloprotenases. Finally, we observed that an exposure of acetylshikonin significantly inhibited the anchorage-independent growth of PANC-1 cells. Together, our results indicate that acetylshikonin could serve as a promising therapeutic agent for future treatment of pancreatic cancer.
- Published
- 2015